GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen Marseille SA (STU:IPK) » Definitions » EBITDA Margin %

Qiagen Marseille (STU:IPK) EBITDA Margin % : 47.04% (As of Dec. 2014)


View and export this data going back to . Start your Free Trial

What is Qiagen Marseille EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Qiagen Marseille's EBITDA for the six months ended in Dec. 2014 was €4.59 Mil. Qiagen Marseille's Revenue for the six months ended in Dec. 2014 was €9.75 Mil. Therefore, Qiagen Marseille's EBITDA margin for the quarter that ended in Dec. 2014 was 47.04%.


Qiagen Marseille EBITDA Margin % Historical Data

The historical data trend for Qiagen Marseille's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen Marseille EBITDA Margin % Chart

Qiagen Marseille Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
EBITDA Margin %
Get a 7-Day Free Trial -34.48 -41.51 33.36 49.74 45.33

Qiagen Marseille Semi-Annual Data
Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.08 78.20 19.71 43.31 47.04

Competitive Comparison of Qiagen Marseille's EBITDA Margin %

For the Diagnostics & Research subindustry, Qiagen Marseille's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qiagen Marseille's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen Marseille's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Qiagen Marseille's EBITDA Margin % falls into.


;
;

Qiagen Marseille EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Qiagen Marseille's EBITDA Margin % for the fiscal year that ended in Dec. 2014 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2014 )/Revenue (A: Dec. 2014 )
=8.16/18.001
=45.33 %

Qiagen Marseille's EBITDA Margin % for the quarter that ended in Dec. 2014 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2014 )/Revenue (Q: Dec. 2014 )
=4.586/9.749
=47.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qiagen Marseille  (STU:IPK) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Qiagen Marseille EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Qiagen Marseille's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Qiagen Marseille Business Description

Traded in Other Exchanges
N/A
Address
Qiagen Marseille SA develops molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

Qiagen Marseille Headlines

No Headlines